"The Devil is in the Details" PharmaVOICE – September 2009 Page 34

...For example, only 9% of U.S. physicians surveyed for a recent Manhattan Research study said they oppose commercial for CME funding, and only 8% of physicians who participated in CME believe that it is biased. In fact, if commercial support is halted, nearly half of the physicians surveyed said they would decrease their use of CME...

... In a prepared statement announcing the study findings, Manhattan Research President Mark Bard observed: “Rather than pulling the plug on a vital source of CME funding, the primary beneficiaries of CME – physicians and patients – would be best served by continued improvements to course availability, offerings, and content through increased collaboration among medical and academic organizations, the pharmaceutical industry, CME providers, and accreditation bodies."